Floatz logo

Atezolizumab

Pancreatic Ductal Adenocarcinoma

Explore 280 assets in Pancreatic Ductal Adenocarcinoma →
Floatz Rating
B62/100
Confidence
Indicative
v0.2
Sponsor
Genentech, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05968326CT.gov
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
—Recruiting———
NCT05867121CT.gov
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
—Completed———
NCT06390059CT.gov
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Pancreatic Ductal Adenocarcinoma

AssetSponsorPhaseRating
Atezolizumab (this asset)Genentech, Inc.P2B · 62
Rmc-6236Tango Therapeutics, Inc.P3BB
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteP2BB
DaraxonrasibRevolution Medicines, Inc.P3BB
S-1Genentech, Inc.P2BB
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)MethanoneCorcept TherapeuticsP3BB
MetforminBritish Columbia Cancer AgencyP2BB
IvospeminPanbela Therapeutics, Inc.P2/3BB
OxaliplatinJonsson Comprehensive Cancer CenterP4BB

+42 more in the Pancreatic Ductal Adenocarcinoma cohort

Other indications for Atezolizumab

IndicationSponsorPhaseRating
Metastatic Neoplasm—P2/3BB · 71
Her2-Receptor Negative Breast Cancer—P2BB · 69
Bladder Transitional Cell Carcinoma—P3BB · 68

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Atezolizumab in Pancreatic Ductal Adenocarcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/atezolizumab-pancreatic-ductal-adenocarcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →